Who are rhFSH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orgovyx, Orilissa, Firmagon, Luveris, Ovidrel, Trelstar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhfsh.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

rhFSH — Competitive Intelligence Brief

rhFSH (rhFSH) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin. Area: Reproductive Medicine / Fertility.

marketed Gonadotropin FSH receptor (FSHR) Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

rhFSH (rhFSH) — Fundación Santiago Dexeus Font. rhFSH (recombinant human follicle-stimulating hormone) stimulates the growth and maturation of ovarian follicles in women by binding to FSH receptors on granulosa cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rhFSH TARGET	rhFSH	Fundación Santiago Dexeus Font	marketed	Gonadotropin	FSH receptor (FSHR)
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01
Orilissa	ELAGOLIX	AbbVie	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2018-01-01
Firmagon	degarelix	Ferring	marketed	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2008-01-01
Luveris	r-hLH	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2004-01-01
Ovidrel	CHORIOGONADOTROPIN ALFA	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2000-01-01
Trelstar	triptorelin	Verity	marketed	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (Gonadotropin class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 4 drugs in this class
Sisli Hamidiye Etfal Training and Research Hospital · 3 drugs in this class
Organon and Co · 3 drugs in this class
Fundación Santiago Dexeus Font · 3 drugs in this class
Merck KGaA · 2 drugs in this class
Nina la Cour Freiesleben · 2 drugs in this class
IVI Madrid · 2 drugs in this class
Dunamenti REK Istenhegyi IVF Center · 1 drug in this class
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 drug in this class
Azienda USL Modena · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rhFSH — Competitive Intelligence Brief. https://druglandscape.com/ci/rhfsh. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab